YM-348 je lek saindazolnim osnovom koji deluje kao potentan i selektivanagonist5-HT2Creceptor, sa EC50 vrednošću od 1 nM i 15x selektivnošću u odnosu na5-HT2A. On je umereno selektivan 3x u odnosu na blisko srodni5-HT2B receptor.[1][2] On ispoljava termogeno ianoreksično dejsto u životinjskim studijama, što ga čini potencijalno korisnim u lečenjugojaznosti.[3][4][5][6]
↑Kimura, Y; Hatanaka, K; Naitou, Y; Maeno, K; Shimada, I; Koakutsu, A; Wanibuchi, F; Yamaguchi, T (2004). „Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist”. European journal of pharmacology483 (1): 37–43. PMID14709324.
↑Shimada, I; Maeno, K; Kazuta, K; Kubota, H; Kimizuka, T; Kimura, Y; Hatanaka, K; Naitou, Y i dr.. (2008). „Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo2,3-gindazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists”. Bioorganic & medicinal chemistry16 (4): 1966–82. DOI:10.1016/j.bmc.2007.10.100. PMID18035544.
↑Hayashi A, Sonoda R, Kimura Y, Takasu T, Suzuki M, Sasamata M, Miyata K (2004). „Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats”. Brain research1011 (2): 221–7. DOI:10.1016/j.brainres.2004.03.032. PMID15157808.
↑Smith, BM; Thomsen, WJ; Grottick, AJ (2006). „The potential use of selective 5-HT2C agonists in treating obesity”. Expert opinion on investigational drugs15 (3): 257–66. DOI:10.1517/13543784.15.3.257. PMID16503763.
↑Nilsson, BM (2006). „5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents”. Journal of medicinal chemistry49 (14): 4023–34. DOI:10.1021/jm058240i. PMID16821762.
↑Wacker, DA; Miller, KJ (2008). „Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases”. Current opinion in drug discovery & development11 (4): 438–45. PMID18600561.
